HN2011002095A - [1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa. - Google Patents

[1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa.

Info

Publication number
HN2011002095A
HN2011002095A HN2011002095A HN2011002095A HN2011002095A HN 2011002095 A HN2011002095 A HN 2011002095A HN 2011002095 A HN2011002095 A HN 2011002095A HN 2011002095 A HN2011002095 A HN 2011002095A HN 2011002095 A HN2011002095 A HN 2011002095A
Authority
HN
Honduras
Prior art keywords
methods
kinase inhibitors
pridins
triazolo
compounds
Prior art date
Application number
HN2011002095A
Other languages
English (en)
Spanish (es)
Inventor
Caroline Leriche
Eric Auclair
Roux Jacques Le
David N Middlemiss
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42229029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2011002095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of HN2011002095A publication Critical patent/HN2011002095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HN2011002095A 2009-02-13 2011-07-29 [1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa. HN2011002095A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09360013 2009-02-13

Publications (1)

Publication Number Publication Date
HN2011002095A true HN2011002095A (es) 2014-01-06

Family

ID=42229029

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011002095A HN2011002095A (es) 2009-02-13 2011-07-29 [1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa.

Country Status (24)

Country Link
US (1) US20120041195A1 (cg-RX-API-DMAC10.html)
EP (1) EP2396324A1 (cg-RX-API-DMAC10.html)
JP (1) JP2012517971A (cg-RX-API-DMAC10.html)
KR (1) KR20110116160A (cg-RX-API-DMAC10.html)
CN (1) CN102317288A (cg-RX-API-DMAC10.html)
AR (1) AR075411A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI1008850A2 (cg-RX-API-DMAC10.html)
CA (1) CA2751517A1 (cg-RX-API-DMAC10.html)
CL (1) CL2011001947A1 (cg-RX-API-DMAC10.html)
CO (1) CO6420343A2 (cg-RX-API-DMAC10.html)
CR (1) CR20110386A (cg-RX-API-DMAC10.html)
DO (1) DOP2011000248A (cg-RX-API-DMAC10.html)
EA (1) EA201101188A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP11011250A (cg-RX-API-DMAC10.html)
HN (1) HN2011002095A (cg-RX-API-DMAC10.html)
IL (1) IL214426A0 (cg-RX-API-DMAC10.html)
MX (1) MX2011008549A (cg-RX-API-DMAC10.html)
NI (1) NI201100151A (cg-RX-API-DMAC10.html)
NZ (1) NZ594508A (cg-RX-API-DMAC10.html)
PE (1) PE20120110A1 (cg-RX-API-DMAC10.html)
SG (1) SG173610A1 (cg-RX-API-DMAC10.html)
TN (1) TN2011000379A1 (cg-RX-API-DMAC10.html)
WO (1) WO2010092041A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201105896B (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TW201204723A (en) * 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
US20140120087A1 (en) 2011-04-21 2014-05-01 Bayer Intellectual Property Gmbh Triazolopyridines
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
CN104603136B (zh) 2012-07-10 2017-06-27 拜耳医药股份有限公司 制备取代的三唑并吡啶的方法
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
CA2914745A1 (en) 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
WO2021098813A1 (zh) * 2019-11-22 2021-05-27 南京明德新药研发有限公司 作为dna-pk抑制剂的嘧啶并吡咯类螺环化合物及其衍生物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
CA2386955A1 (en) 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
AU2003297161B8 (en) * 2002-12-18 2011-03-31 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2005037285A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
NZ588896A (en) 2004-08-25 2012-05-25 Targegen Inc Heterocyclic compounds and methods of use
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006101977A2 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
EP1878727A4 (en) 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
WO2006133411A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
WO2007067537A1 (en) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
JP5336375B2 (ja) * 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
EP2076513A1 (en) * 2006-10-20 2009-07-08 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
CA2673003A1 (en) 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2009259853A1 (en) * 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
PE20110063A1 (es) * 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010010189A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
UY32045A (es) * 2008-08-12 2010-03-26 Takeda Pharmaceutical Compuesto amida
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法

Also Published As

Publication number Publication date
BRPI1008850A2 (pt) 2016-03-15
IL214426A0 (en) 2011-09-27
CR20110386A (es) 2011-12-02
JP2012517971A (ja) 2012-08-09
ECSP11011250A (es) 2011-10-31
NI201100151A (es) 2012-10-03
AR075411A1 (es) 2011-03-30
SG173610A1 (en) 2011-09-29
US20120041195A1 (en) 2012-02-16
EA201101188A1 (ru) 2012-04-30
EP2396324A1 (en) 2011-12-21
MX2011008549A (es) 2011-12-06
WO2010092041A1 (en) 2010-08-19
CO6420343A2 (es) 2012-04-16
CA2751517A1 (en) 2010-08-19
DOP2011000248A (es) 2011-10-31
CL2011001947A1 (es) 2012-03-16
NZ594508A (en) 2013-12-20
ZA201105896B (en) 2012-03-28
TN2011000379A1 (en) 2013-03-27
KR20110116160A (ko) 2011-10-25
CN102317288A (zh) 2012-01-11
PE20120110A1 (es) 2012-02-20

Similar Documents

Publication Publication Date Title
CR20110386A (es) 1, 2, 4] triazolo [1, 5 -a] piridinas como inhibidores de cinasa
CO6930356A2 (es) Compuestos inhibidores de metaloenzimas
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
CO6940433A2 (es) Compuestos inhibidores de metaloenzimas
EA201171367A1 (ru) Винилиндазолильные соединения
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
UY37018A (es) Inhibidores bicíclicos de pad4
WO2008124849A3 (en) Pyrrolo-pyridine kinase modulators
MX386224B (es) Activadores de cinasa de piruvato para su uso en terapia.
CU24396B1 (es) Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
CR10995A (es) Inhibidores de la actividad de akt
JOP20140141B1 (ar) استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية
PH12013502622A1 (en) Metalloenzyme inhibitor compounds
CR20110368A (es) Compuestos de quinazolina sustituidos
WO2013077921A3 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
MY162950A (en) Compounds and methods for kinase modulation, and indications therefor
UY33931A (es) Agentes de union biespecificos
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
UY32291A (es) Inhibidores de quinasa con perfiles de seguridad cyp mejorados
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
PT2928477T (pt) Utilização do inibidor da telomerase imetelstat para o tratamento de mielofibrose.
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
WO2012178015A3 (en) Lrrk2 inhibitors
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica